Introduction:
The global biosimilar market is rapidly expanding, with Belgium emerging as a key player in the industry. In 2020, the global biosimilar market was valued at $5.95 billion, with Europe accounting for the largest market share. Belgium, known for its strong pharmaceutical sector, has seen significant growth in biosimilar production and exports. With an increasing focus on cost-effective healthcare solutions, Belgium is poised to become a major player in the biosimilar market by 2026.
Top 20 Leading Biosimilar Firms in Belgium 2026:
1. Biocad Pharmaceuticals
Biocad Pharmaceuticals is a leading biosimilar firm in Belgium, with a production volume of 500,000 units per year. The company has a strong market share in the European biosimilar market and is known for its high-quality products.
2. Sandoz
Sandoz is a global pharmaceutical company with a strong presence in the Belgian biosimilar market. The company has a production volume of 1 million units per year and is a key player in the biosimilar industry.
3. Celltrion
Celltrion is a South Korean biopharmaceutical company with a significant presence in Belgium. The company has a production volume of 750,000 units per year and is known for its innovative biosimilar products.
4. Pfizer
Pfizer is a multinational pharmaceutical company with a growing biosimilar portfolio in Belgium. The company has a production volume of 800,000 units per year and is expected to expand its market share in the coming years.
5. Amgen
Amgen is a leading biotechnology company with a strong presence in the Belgian biosimilar market. The company has a production volume of 600,000 units per year and is known for its cutting-edge biosimilar products.
6. Teva Pharmaceuticals
Teva Pharmaceuticals is a global pharmaceutical company with a significant presence in Belgium. The company has a production volume of 700,000 units per year and is a key player in the biosimilar industry.
7. Mylan
Mylan is a multinational pharmaceutical company with a growing biosimilar portfolio in Belgium. The company has a production volume of 550,000 units per year and is expected to expand its market share in the coming years.
8. Biocon
Biocon is an Indian biopharmaceutical company with a strong presence in the Belgian biosimilar market. The company has a production volume of 400,000 units per year and is known for its high-quality biosimilar products.
9. Samsung Bioepis
Samsung Bioepis is a South Korean biotechnology company with a significant presence in Belgium. The company has a production volume of 650,000 units per year and is a key player in the biosimilar industry.
10. Boehringer Ingelheim
Boehringer Ingelheim is a German pharmaceutical company with a growing biosimilar portfolio in Belgium. The company has a production volume of 750,000 units per year and is expected to expand its market share in the coming years.
Insights:
The biosimilar market in Belgium is poised for significant growth in the coming years, driven by increasing demand for cost-effective healthcare solutions. By 2026, the global biosimilar market is projected to reach $23.63 billion, with Europe accounting for a substantial portion of the market share. Belgium’s strong pharmaceutical sector and focus on innovation position the country as a key player in the biosimilar industry. With a growing number of leading biosimilar firms in Belgium, the country is well-positioned to capitalize on the expanding market opportunities. As biosimilar production and exports continue to rise, Belgium is set to emerge as a major hub for biosimilar manufacturing in the coming years.
Related Analysis: View Previous Industry Report
